A series of proteolytic fragments of human von Willebrand Factor (vWF) was purified t o characterize the functional site that supports its interaction with sulfatides. Splll, an N-terminal homodimer generated by V-8 protease (amino acids [AA] 1 t o 1365), bound t o sulfatides in a dose-dependent and saturable way. Splll also totally inhibited the binding of vWF t o sulfatides and Splll binding was completely abolished by vWF. In contrast, Spll, the complementary C-terminal homodimer (AA 1366 to 2050). did not exhibit any binding affinity for sulfatides. Four purified fragments overlapping the sequence of Splll were also tested for their ability t o interact with sulfatides. An N-terminal monomeric 34-Kd fragment (P34, AA 1 to 272) generated by plasmin, a central monomer (Spl, AA 911 t o 1365) produced by digestion with V-8 protease, and a tetrameric fragment lll-T2 (comprising a pair of the two sequences 273 t o 51 1 and AA 674 t o 728) produced by secondary digestion of Splll with trypsin did not interact with sulfatides. In contrast, a monomeric 39/34-Kd fragment produced by dispase (AA 480 to 718) bound specifi-
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UMAN von Willebrand Factor (vWF) is essential for
H platelet adhesion to the subendothelium of injured capillary vessels where blood circulates with a high wall shear rate. vWF is a glycoprotein (GP) that appears as a set of multimers when analyzed by sodium dodecyl sulfate (SDS)-agarose gel electrophoresis with apparent molecular weights (mol wt) ranging from 0.5 to more than 15 million daltons. Each multimer is composed by the association of 275-Kd subunits through multiple disulfide bonds, the protomer being the 550-Kd dimer.' The vWF subunit is composed of 2,050 amino acids (AA) containing 22 oligosaccharide chains. ' Based on antibody, proteolytic fragment, and synthetic peptide analysis, it has been established that the biologic activity of vWF results from its capacity to bridge platelets to the subendothelium. This is mediated by distinct functional domains on the subunit, each specifically interacting with a constituent of either platelets or subendothelium. vWF binds to platelets via two distinct membrane receptors, ie, the GPIb3'6 and the GPIIb/IIIa." The GpIbbinding site of vWF was first localized on the N-terminal homodimeric fragment SpIII (AA 1 to 1365) obtained after digestion of vWF by V-8 protease,Lo,'' and more recently on a short domain composed of two discontinuous sequences (AA 474 to 488 and 694 to 708)'' brought in a close spatial relationship via intrachain disufide bridges. 13 The GpIIb/ cally and with a high affinity to sulfatides and totally displaced vWF or Splll binding. Conversely, binding of the 39/34-Kd species was totally abolished by vWF or Splll. Thus, a functional site responsible for sulfatide binding was localized between AA 480 and 718 and comparison of the binding properties of the 39/34-Kd and lll-T2 fragments indicated that the sequence 512 t o 673 is necessary for the binding t o sulfatides. Further mapping of this new functional domain of vWF, based on experiments of competitive inhibition of binding by either heparin or monoclonal antibodies directed toward vWF, showed that the site interacting with sulfatides is distinct from those involved in binding t o platelet glycoprotein Ib, collagen, or heparin. This finding was confirmed by experiments using synthetic peptides which also indicated that the sequence comprising AA 569 t o 584 is part of the sulfatide-binding domain or influences its activity.
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IIIa-binding domain of vWF has been localized on the C-terminal homodimeric fragment SpII" generated by V-8 protease (AA 1366 to 2050).1° The capacity of vWF to interact with platelet GpIIb/IIIa may be related to the presence of an RGD ~equence'~ (AA 1744 to 1746)' known to be a versatile cell recognition signal of extracellular matrix or plasma adhesive proteins interacting with cell surface receptor molecules. Two distinct domains interacting with fibrillar collagen have been identified. One is located on the monomeric fragment SpI" generated by V-8 protease (AA 911 to 1365),"' between residues 911 and 1114.16 Using tryptic digestion of vWF, a second collagen binding domain has been identified on a 116-Kd dimeric species (52/48-Kd fragment)16." extending from residues 449 to 728.I8.l9 A further study established that the two sequences 542 to 622 and 948 to 998, respectively, included in the two previous fragments, are binding sites of vWF for monomeric type TI1 collagen.z0 Two distinct domains interacting with heparin have also been identified, indicating that vWF may potentially bind to heparinlike glycosaminoglycans of the subendothelium. One site is localized on an N-terminal monomeric 34-Kd fragment of vWF produced by plasmin (P34)" or trypsin (T4) and extending from AA 1 to 272.22 The second heparin binding site has been identified on the tryptic 52/48-Kd fragment (AA 449 to 728)" and on a monomeric 39/34-Kd dispase fragment lying between AA 480 and 718.13 However, an overlapping fragment 111-T2, produced by secondary digestion of SpIII and composed of two heavy chains (AA 273-511) and two light chains (AA 674-728)," does not support heparin binding,23 suggesting that the sequence 512 to 673 is essential for vWF to interact with heparin. Other studies showed that among the adhesive proteins, vWF, thrombospondin, and laminin are similar in their ability to agglutinate fixed erythrocyte~.'~.'~ A line of evidence strongly suggested that this function results from the capacity of these protein^^^. ' For personal use only. on October 23, 2017. by guest www.bloodjournal.org From bind specifically and with a high affinity to sulfatide (galactosyl ceramide-13-sulfate), a component present in the membrane of cells including platelets and erythrocytes.
In the present report we investigated the sulfatidebinding domain(s) of vWF. For this purpose a series of well-localized proteolytic fragments of vWF was purified and analyzed for their capacity to bind or to inhibit vWF binding to sulfatides in a solid-phase system. Our data indicate that a domain responsible for binding to sulfatides is localized on the 39/34-Kd fragment (AA 480 to 718) of vWF. Other portions of vWF subunit did not exhibit any affinity for sulfatides. The functional site appears distinct from those involved in the binding to heparin and GPIb. The sequence comprising AA 512 to 673 appears necessary for binding to sulfatides and experiments of inhibition of binding by synthetic peptides suggest that the sequence comprising AA 569 to 584 is part of the sulfatide-binding domain or influences its activity.
MATERIALS AND METHODS
Purification of vWF and of proteolytic fragments. Human vWF was purified from lyophilized factor VIII/vWF concentrates (gift from the Centre National de Transfusion Sanguine, Les Ulis, France) essentially as described elsewhere." The purified vWF contains -200 U vWF Agimg of protein and trace amounts (<0.1% wt/wt) of fibrinogen and fibronectin as estimated by radioimmunoassay. Purified vWF in imidazole-HCl buffer (20 mmol/L imidazole-HC1, 0.15 mol/L NaC1, 0.02% NaN,, pH 6.8) was concentrated by precipitation with 40% saturated ammonium sulfate and stored as a paste at -80°C before use.
Digestion of vWF by Stuphyloccocus aureus V-8 protease (V-8 protease) (Miles, Paris, France) was performed using the enzyme coupled to Sepharose 2B (Pharmacia, Uppsala, Sweden). Proteolytic fragments SpI (monomer, AA 911 to 1365), SpII (dimer, 1366 to 2050), and SpIII (dimer, AA 1 to 1365) were purified as previously described"'," using ion-exchange chromatography on DEAE-Sephacel (Pharmacia) gel filtration on G150 Sephadex (Pharmacia), and immunoadsorption of contaminants onto Sepharose-coupled selected monoclonal antibodies (MoAbs) to human vWF.
Monomeric P34 fragment covering the N-terminal end of vWF (AA 1 to 272)2' was obtained by digesting purified SpIII (0.5 to 1.0 mg/mL) in 50 mmol/L Na,HPO,-H,PO, buffer, 80 mmol/L NaCI, pH 7.4, for 24 hours at 22°C with plasmin (Boehringer, Meylan, France) using an enzyme-substrate ratio of 1/20. Proteolysis was terminated with 1 mmol/L (final concentration) of diisopropylfluorophosphate (DFP). The digest was concentrated by lyophilization and dissolved in TBS (25 mmol/L Tris-HCI, 0.15 mol/L NaCI, pH 7.4) containing 6 mol/L guanidinium chloride. It was then submitted to gel filtration on Sepharose 4B and eluted with the same buffer. The protein peak containing the P34 fragment was extensively dialyzed against distilled water and lyophilized. The P34 fragment was finally dissolved in a minimal volume of TBS containing 6 mol/L guanidinium chloride, extensively dialyzed against TBS, and stored at -80°C before use.
The monomeric 39/34-Kd fragment of vWF (AA 480 to 718) was obtained by digestion of purified vWF with dispase (Boehringer) as described by Andrews et al." vWF (1 mg/mL) in TBS containing 0.2 mmol/L CaCl, was digested by dispase for 18 hours at 22°C using an enzyme/substrate ratio of 1/5. The reaction was terminated by addition of EDTA (10 mmol/L final concentration). The 39/34-Kd fragment was purified as described'' by affinity chromatography onto heparin-Sepharose (Pharmacia) in TBS. After The tetrameric III-T2 fragment comprising the two sequences AA 273 to 511 and AA 674 to 72822 was produced by digestion of purified SpIII (1 mg/mL in TBS) by TPCK-trypsin (Millipore, Freehold, NJ) at an enzyme/substrate ratio of 1/50 for 18 hours at 22°C. The reaction was stopped by addition of 2 mmol/L DFP. The digest was chromatographed onto heparin-Sepharose equilibrated in TBS. The pass-through containing the 111-T2 fragment was then submitted to gel filtration on Sephadex S 200 HR (Pharmacia) using TBS containing 6 mol/L guanidinium chloride as eluant. After extensive dialysis against TBS and lyophilization, purified 111-T2 fragment was separated by gel filtration onto Sepharose CL-4B eluted with TBS. Purified fragment was stored at -80°C until use.
The localization within the vWF subunit of the purified proteolytic fragments is indicated on Fig 1 . Radiolabeling ofproteins. vWF, proteolytic fragments, and antibodies to vWF were labeled with N a 9 (Amersham, Les Ulis, France) using Iodo-Gen (Pierce Chemical Co, Rockford, IL) as described by Fraker and S p e~k . '~ Specific radioactivity was from 0.03 to 2 pCi/pg for proteins used as ligands to determine isotherms of binding to sulfatides. It was -0.5 to 10 pCi/pg for competitive inhibition of binding of 12sI-ligands to sulfatides and for the determination of the purity of proteins by gel electrophoresis.
For Western blots the specific radioactivity of antibodies was -2.5 pCi/pg. The labeled proteins were stored at 4°C and used within 5 days for vWF, 2 days for vWF proteolytic fragments, and 2 months for antibodies.
A solid-phase assay was developed according to the method of Roberts et a126 using sulfatides coated on 96-well microtiter plates (Dynatech, Marnes-La-Coquette, France), with slight modifications. Aliquots (100 pL) of diluted sulfatides (Sigma, La Verpillibre, France) in 100% methanol were introduced in the wells of microtiter plates and dried under nitrogen. Wells treated with methanol alone in the absence of sulfatides were used as controls. Nonspecific binding sites were blocked by incubating the plates in Tris/BSA (50 mmol/L Tris-HC1,llO mmol/L NaCI, 5 mmol/L CaCl,, 1% bovine serum albumin [BSA], 0.1 mmol/L phenylmethylsulfonyl fluoride [PMSF], 0.02% NaN,, pH 7.8) for 1 hour at 37°C. Following aspiration of the buffer, dilutions of '%vWF or '251-fragments in Tris/BSA, centrifuged for 5 minutes at 10,OOOg immediately before use, were added to the wells (100 pL) and incubated for 18 hours at 22°C. The supernatants were aspirated and the plates were washed four times with TrisiBSA. After drying the wells were cut and the associated radioactivity was counted in a 1260 multigamma I1 counter (LKB Instruments AB, Bromma, Sweden). In some experiments sulfatide-bound '2SI-ligand was extracted by incubating the wells with 100 JLL of 5% SDS in 125 mmol/L Tris-HC1 buffer, pH 6.8 for 1 hour at 22°C. The supernatants containing more than 80% of the radioactive material were then analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in comparison with the starting '2sI-ligand.
Using varying concentrations (0 to 300 pg/mL, ie, 0 to 30 pg/well) of sulfatides for coating and a constant concentration of IZI-vWF (final concentration 0.5 pg/mL, 50 ngiwell), the concentration of sulfatides for optimal binding of '2sI-vWF was determined to be 12 pg/well(l20 pg/mL). This concentration was used in all of the following experiments. Kinetics of binding of '"I-vWF (0.5 pg/mL) to coated sulfatides (12 pg/well) were studied at 22°C between 30 minutes and 48 hours. At selected times the reaction was stopped by aspiration of the supernatants and wells were counted. Results showed that a maximum binding was reached after 6 hours and that no significant modification of the equilibrium occurred for 48 hours.
Synthetic peptides.
Binding of '"I-vWF or fragments to sulfatides.
Inhibition of binding of "-TvWF or '%vWF fragments to sulfatides by unlabeled proteins, synthetic peptides, heparin or antibodies was performed using a modified binding assay. lZsIligand at a final concentration of 0.5 pg/mL was premixed with serial dilutions of unlabeled competitor with final concentrations varying from 0.5 to 250 pg/mL for vWF or vWF fragments, from -6 to 1,200 pmol/L for peptides and from 15 to 2,000 pg/mL for heparin. IgG at a final concentration between 7.5 and 120 pg/mL was preincubated with 'Wigand for 30 minutes at 37°C before starting the binding assay. After centrifugation for 5 minutes at 10,OOOg the supernatants were incubated onto sulfatide-coated wells and the assay was continued as described previously. Results were expressed by comparison with the specific binding of IzIligand estimated in the absence of competitor.
Binding of '2sI-v WF to ristocetin-treated platelets or to collagen and inhibition by MoAbs. Binding of 'ZSI-~WF to ristocetin-treated platelets and inhibition of the binding by MoAbs to vWF were performed using fresh washed platelets (lo8 cells/mL) and 1 mg/mL of ristocetin (Lunbeck and Co, Copenhagen, Denmark) as previously described.''
Binding of '2sI-~WF to collagen and its inhibition by MoAbs to vWF were performed using human fibrillar type 111 collagen (Sigma) according to the method already described."
SDS-polyacrylamide slab gels with a linear gradient (3.5% to 20%) of polyacrylamide were performed in a discontinuous buffer system according to the method of Laemmli3' using a 3.5% polyacrylamide stacking gel. SDS-agarose slab gels (0.1% SDS, 6 mol/L urea, 1.5% acrylamide, 1% agarose, 6 mol/L EDTA in 0.1 mol/L Tris-phosphate buffer, pH 7) were performed as previously described' using agarose Sea-kem HGT (Eurobio, Les Ulis, France). Markers included low mol wt standards (Pharmacia), purified IgG (mol wt 160 Kd), fibronectin (mol wt 440 Kd), fibrinogen (mol wt 340 Kd), and IgM (mol wt 900 Kd). Gels were stained with Coomassie blue and dried. Radioactive material was shown by autoradiography of the dried gels performed at -80°C using Kodak X-Omat S films and X-Omatic cassettes (Eastman Kodak Co, Rochester, NY). Alternatively, polyacrylamide gels were electroblotted onto nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany).-'* Transferred proteins were incubated with Y-MoAb or polyclonal anti-vWF IgG. After extensive washing with 0.15 mol/L NaCI, the reactive proteins were displayed by autoradiography.
SDS-gel electrophoresis and Westem blots.

RESULTS
Localization of a sulfatide binding site on proteoEytic fragments of vWF by direct binding. Table 1 compares the capacity of binding to coated sulfatides (12 Fg/mL) of IzI-vWF and of '251-proteolytic fragments used at a final concentration of 0.5 kg/mL. Results expressed as percent of bound to total radioactivity show that SpIII fragment significantly bound to sulfatides (B/T -8%) when compared with nonspecific binding estimated on uncoated wells (B/T I 0.2%). The binding affinity of SpIII appeared lower than that of intact vWF at the same concentration (B/T -32%). In contrast, '2sI-SpII was unable to bind to sulfatides (B/T < 0.2%). Among the four other fragments tested (P34, 39/34-Kd fragment, 111-T2, and SpI), only the 39/34-Kd fragment was capable of interacting with sulfatides (B/T -4%) as compared with nonspecific binding (B/T 5 0.15%). In contrast, binding of P34,III-T2, and SpI was not significantly distinct from the nonspecific binding on repeated testing.
Sulfatide-bound 39/34-Kd fragment was analyzed after "Sl-fragment~ or vWF was incubated at the final concentration of 0.5 pg/mL (50 ng/well) into wells coated with 12 pg of sulfatides, and the binding assay was performed as described in Materials and Methods. Nonspecific binding estimated using uncoated wells was less than 0.2% for all of the "51-fragment~ and -1.5% for "I-vWF. Specific radioactivity was 2 x 10' cpm/pg for vWF, 9 x lo* cpm/pg for Splll, 9.4 x 108cpm/pgforSpll,4.3 x lO'cpm/pgforSpI, 10.4 x 10'cpm/pg for P34.6 x 10' cpmlpg for fragment 39/34 Kd, and 3.9 x 10' cpmlpg for fragment llbT2.
extraction, by SDS-PAGE and compared with the starting "'I-ligand (Fig 2) . The material bound to sulfatides had the same pattern and mobility as the purified ligand that appeared as a doublet with mol wt of 39 and 34 Kd. No other band could be detected even after prolonged autoradiography.
The presence of a sulfatide-interacting domain on SpIII and the 39/34-Kd fragment was confirmed by studying the concentration dependence of their binding to sulfatides in comparison with "'I-vWF. With the three ligands (Fig 3) , results interpretable as specific and saturable binding to sulfatides were observed. The total amount of bound vWF (Fig 3A) increased from 3.7 to 425 ng/well as concentrations of added "'I-vWF increased from 0.1 to 100 pg/mL (0.01 to 10 pg/well). Nonspecific binding linearly increased to 140 ng/well at the highest concentration of vWF tested.
When '"I-SpIII was used as ligand (Fig 3B) , the total amount of bound lL'I-SpIII varied from 9.2 to 252 ng/well when the added concentration increased from 2.2 to 360 pg/mL (0.22 to 36 kg/well). Nonspecific binding linearly increased from 0.45 to 67 ng/well in that range of concentrations.
Similarly, binding of the 39/34-Kd fragment also appeared concentration dependent and saturable (Fig 3C) . The total amount bound varied from 5.8 to 200 ng/well when the concentration increased from 2.5 to 500 pg/mL, whereas the nonspecific binding reached 20 ng/well at the highest concentration used.
The binding parameters derived by Scatchard analysis from the specific binding curves for vWF (Fig 3D) , SpIII (Fig 3E) , and the 39/34-Kd fragment (Fig 3F) indicated that the three ligands interacted with a single class of sites (r = .95, .90, and .96, respectively). At saturation, the binding was 280 ng/well for "'1-vWF, 200 ng/well for SpIII, and 240 ng/well for 39/34-Kd species (ie, 23, 16.7, and 20 ng/ pg of sulfatides). The apparent constants of dissociation (kd) were -1.9 x lo-", 3.3 x lo-', and 3.2 x mol/L, respectively, assuming a mol wt of 275, 170, and 39 Kd for the subunit of each ligand.
Localization of a sulfntide binding site on proteo[ytic fragments of vWF by competitive inhibition. Purified fragments SpIII, SpII, SpI, and fragment 39/34 Kd were compared with vWF for their ability to inhibit binding of the labeled ligands to sulfatides. When lZSI-vWFwas used as ligand (Fig  4) , unlabeled vWF completely inhibited the binding at the concentration of -100 pg/mL. Half-maximum inhibition was reached with 4 pg/mL (15 nmol/L). Assuming a mol wt of 275 Kd for the subunit, the apparent kd that derived was 2.9 x lo-' mol/L. In addition, we observed (Fig 4) that SpIII completely inhibited the vWF binding and the 39/ 34-Kd fragment almost completely abolished it at the highest concentration used (250 pg/mL). Half-maximum ---1 2 After incubation of the lXl-39/34-Kd fragment with immobilized sulfatides, the bound protein was extracted as described in Materials and Methods. Electrophoresis was performed using SDS-polyacrylamide (3.5% t o 20% gradient) gels. Lane 1, Ix1-39/34-Kd fragment used as ligand (-48,000 cpm, 12 ng). Lane 2, '=I-39/34-Kd fragment was incubated with sulfatide-coated wells (50 ng/well containing 12 pg of sulfatides). Bound radioactivity was -5% of the total. After washing the bound radioactivity of five wells was extracted using 100 pL of 5% SDS in 0.125 mmol/L Tris-HCI buffer, pH 6.8 and the recovered radioactivity (-41,000 cpm) was loaded on the gel. Position of the mol wt markers is indicated on the left. tration 0.5 pg/mL, specific radioactivity -lo7 cpm/pg) was premixed with increasing concentrations of unlabeled protein (0 t o 250 pg/mL final concentration). After centrifugation, the mixture (100 pL) was incubated at 22°C into sulfatide-coated wells (12 pg/well) and the binding assay was performed as described in Materials and Methods. In the absence of competitor, the total binding was 30% of the applied radioactivity. Nonspecific binding of '"I-vWF was less than 2% and did not significantly vary with the concentration of unlabeled protein added. Results (mean f SD, n = 3) are expressed as the percentage of inhibition of specific binding estimated in the absence of competitor. inhibition was observed at 10.6 pg/mL and 47 pg/mL for SpIII and the 39/34-Kd fragment, respectively. In contrast, even used at 250 pg/mL, SpII and SpI were unable to compete for the binding of '"I-vWF to sulfatides. Similarly, experiments using lzI-SpIII and Iz5I-39/34-Kd fragments as ligands confirmed the presence of binding sites of vWF to sulfatides on SpIII as well as on the 39/34-Kd fragment (not shown). At 250 pg/mL of competitor, binding of 'zI-SpIII was abolished to more than 85% by vWF or SpIII. The respective half-maximum inhibition was reached at 10.5 pg/mL (39 nmol/L of vWF) and 14.5 pg/mL (85.3 nmol/L of SpIII), and the apparent kd of '"I-SpIII binding by unlabeled SpIII was 4.3 x lo-' mol/L. More than 85% of binding of Iz5I-39/34-Kd fragment was inhibited in the presence of 250 pg/mL of either vWF or 39/34-Kd fragment. The half-maximum inhibition was reached with 4.2 pg/mL of vWF (15.6 nmol/L) and 11.5 pg/mL of 39/34 Kd (290 nmol/L). The apparent kd of 'ZSI-ligand binding by the unlabeled 39/34-Kd fragment was 2 x When heparin was tested as competitor at a final concentration ranging from 15 to 2,000 pg/mL, no significant effect was detected on the binding of '"I-vWF, SpIII, and the 39/34-Kd fragment to sulfatides (not shown). 
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block the binding of vWF or of its fragments to ristocetintreated platelets. Conversely, MoAb 724, which by immunoblot recognized the 39/34-Kd fragment but not 111-T2 species, was unable to inhibit binding of vWF to ristocetintreated platelets and to collagen (data not shown). In contrast, a polyclonal antibody to vWF used as control totally abolished binding of 12'I-vWF to sulfatides at the lowest concentration used (7.5 Fg/mL), but had no significant effect on the binding of the vWF fragments, even at 120 pg/mL.
Inhibition 
DISCUSSION
vWF mediates platelet adhesion to the subendothelium. This capacity has been related to the presence of multiple functional sites along the vWF subunit interacting either with components of the subendothelium like collagen"^''^" or heparinlike m01ecules,'~~'~~~'~~' or with GPs of the platelet membrane, ie, GPIb'"3,18.23 and GPIIb/IIIa." vWF has also been shown to be capable of inducing agglutination of aldehyde-fixed erythrocytes, and this property has been related to the presence of a specific site of vWF involved in binding to sulfatides (galact~sylceramide-I~-sulfate)~~ located on the membrane?6'28 However, the portion of the vWF molecule implicated in its interaction with sulfatides has not yet been elucidated. Thus, we attempted to precisely localize the sulfatide-binding domain within the sequence of vWF subunit; for this, we prepared a series of well-defined fragments of vWF and compared them with vWF in a solid-phase assay for their capacity to interact with immobilized sulfatides.
Direct-binding experiments and Scatchard plots derived from the specific binding curves confirmed results already reported in the literature,26 that vWF binds to sulfatides in a specific and saturable fashion. The specificity and saturability of the binding are further supported by the capacity of unlabeled vWF to inhibit competitively the binding of '2sI-vWF with the same apparent affinity. In addition, specificity of the binding is indicated by the failure of related proteins such as SpII, the homodimeric fragment (AA 1366 to 2050)," to interact with sulfatides by either direct binding or competitive inhibition studies. The localization of a sulfatide-binding domain on SpIII, a homodimer of the N-terminal portion of vWF subunit (AA 1 to 1365) generated by digestion with V-8 protease," was established by showing that the labeled fragment binds specifically and with a high affinity to sulfatides in a dose-dependent and saturable way. This finding was conFor personal use only. on October 23, 2017. by guest www.bloodjournal.org From firmed by experiments of competitive inhibition showing that unlabeled SpIII inhibits lzI-SpIII binding with the same apparent affinity. '"I-vWF binding can also be totally abolished by SpIII and I2'I-SpIII binding by vWF. Thus, our data strongly suggested that the two species have the interactive site for sulfatides in common.
A more precise localization of the specific domain for sulfatides relied on the use of purified monomeric fragments overlapping the sequence of SpIII, P34 (AA 1-272)F SpI (AA 911 to 1365)," and 39/34-Kd (AA 480 to 718)13 generated by secondary digestion of SpIII by plasmin or V-8 protease or of vWF by dispase, respectively. Among those only the 39/34-Kd fragment showed the ability to specifically bind to sulfatides. In addition, characterization of the sulfatide-bound material by gel electrophoresis confirmed that the 39/34-Kd fragment did bind specifically and that no other protein accounted for the binding. The presence of a binding site of vWF on the 39134-Kd fragment was confirmed by experiments of competitive inhibition. "'I-39/ 34-Kd fragment binding was totally inhibited by unlabeled 39/34-Kd fragment with a similar apparent affinity. This binding was also totally abolished by vWF and binding of 12'I-vWF by the 39/34-Kd fragment. Therefore, our data, which clearly showed that fragments P34 and SpI are devoid of affinity for sulfatides, also strongly suggested the absence of interactive sites outside the sequence 480 to 718 of vWF subunit.
It has been recently established that the 39134-Kd fragment comprises several functional domains of vWF, including unrelated binding domains for heparin, collagen, and platelet GPIb." Thus, it was of interest to analyze whether the site presently determined to be involved in binding to sulfatides may overlap one of the others.
Our data using inhibition of binding to sulfatides by MoAbs to vWF, synthetic peptides, and heparin bring a line of evidence to support that the sulfatide-interacting site is independent from the others. The lack of inhibition of binding to sulfatides of vWF, SpIII, or the 39134-Kd fragment by MoAb 322, known to specifically block vWF binding to ristocetin-treated platelets, strongly suggested that vWF binding sites for GPIb and sulfatides were unrelated. Additional evidence was derived from our data of inhibition of binding to sulfatides using MoAb 724 specific for the 39/34-Kd fragment. This MoAb identified as a strong inhibitor of vWF binding to sulfatides was totally unable to affect vWF binding to ristocetin-treated platelets. In addition, our observation that MoAb 724 had no effect on vWF binding to human fibrillar collagen also supports that the collagen binding and sulfatide binding domains of vWF are distinct. The existence of a specific site for sulfatides was further illustrated by experiments of competive inhibition performed using synthetic peptides derived from the sequence of vWF subunit. Our data showed that two peptides extending between residues 474 to 488 and 692 to 708, and previously characterized as potent inhibitors of vWF binding to GPIb in the presence of ristocetin,12.35 were unable to interact with the binding of vWF, SpIII, or the 39/34-Kd fragment to sulfatides. Similarly, our data showed that fragment 111-T2, a tetramer comprising the two sequences AA 273 to 511 and AA 674 to 72822 generated by secondary digestion of SpIII by trypsin and known to interact with GPIb,23 was unable to bind to sulfatides and to MoAb 724. Thus, it appears from our experiments using either MoAbs or synthetic peptides that the sulfatide binding site of vWF is distinct from those interacting with either GPIb or collagen.
There is also evidence that the sulfatide binding domain is distinct from that involved in heparin binding. Thus, our results showed that heparin, even used at high concentration, was unable to inhibit binding of vWF, SpIII, or 39/34-Kd species, confirming previous data from Roberts et using vWF. Further localization of the sulfatide-binding domain was derived from the comparison of the binding capacity to sulfatides of the 39/34-Kd fragment (AA 480 to 718) and 111-T2 fragment (AA 273 to 511, 674 to 728), indicating that the sequence 512 to 673, missing in the 111-"2 species, was required for vWF binding to sulfatides. We then established that the peptide lying between AA 569 and 584 strongly inhibited the interaction between sulfatides and vWF or its two fragments. This finding confirms the similarity of binding properties to sulfatides of vWF, SpIII, and the 39/34-Kd fragment and the identity of the binding sequences of the three species as already indicated by our experiments of reciprocal competitive inhibition of binding. Sulfatides have been identified on the platelet In addition, recent data from Data et a139 established that unstimulated platelets adhere to sulfatides and that this adhesion is mediated by vWF. Therefore, the new functional domain that we identified may play a role in the interaction of vWF with its platelet receptors, and our results indicate that the sequence 569 to 584 of vWF is part of the interactive site for sulfatides or may influence its activity.
